Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medicaid Coverage topic
No spam. Unsubscribe anytime.
Committee advances bill to align Medicaid coverage with new FDA approvals and create rare‑disease advisory council
Summary
Senate Bill 143 would require Arkansas Medicaid to cover new products and label expansions approved by the U.S. FDA and establish a rare disease advisory council to aid coverage decisions; sponsors described the measure as a patient‑advocacy effort.
Senator Irvin presented Senate Bill 143 to the committee, describing it as a patient‑advocacy measure that would ensure Arkansas Medicaid beneficiaries have access to newly FDA‑approved drugs and label expansions. The bill also creates a rare disease advisory council intended to bring clinical expertise to coverage and prior‑authorization decisions.
Irvin told the committee Arkansas is one of only four states that does not provide immediate access to drugs following FDA approval and said the bill would create clearer processes and better communication between treating physicians and Medicaid decision makers. He said the Department of Human Services helped develop definitions in the draft.
Senator Hamble and other members asked whether the bill would cover drugs approved by the FDA for specific rare‑disease indications and whether the advisory council could prevent access; Irvin said the council’s purpose is to facilitate approvals and help clinicians and payers make informed decisions so patients receive treatment.
No public testimony opposed the bill. Senator Irvin asked for a favorable vote; the committee moved, and the bill passed by voice vote.
Next steps: SB 143 passed out of committee and will proceed through the legislative process; sponsors said DHS and other stakeholders collaborated on the draft.
